Details of the Drug

General Information of Drug (ID: DMR5ZUP)

Drug Name
Paramethadione
Synonyms
Isoethadione; Paradione; Parametadiona; Parametadione; Paramethadionum; Parametadione [DCIT]; A 348; Paradione (TN); Parametadiona [INN-Spanish]; Paramethadione (INN); Paramethadione [BAN:INN]; Paramethadione [INN:BAN]; Paramethadionum [INN-Latin]; 3,5-Dimethyl-5-ethyloxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-2,4-oxazolidinedione
Indication
Disease Entry ICD 11 Status REF
Absence epilepsy N.A. Approved [1]
Epilepsy 8A60-8A68 Approved [1]
Fetal trimethadione syndrome LD2F.0Y Approved [2]
Seizure disorder 8A6Z Approved [2]
Therapeutic Class
Anticonvulsants
Affected Organisms
Humans and other mammals
ATC Code
N03AC01: Paramethadione
N03AC: Oxazolidine derivatives
N03A: ANTIEPILEPTICS
N03: ANTIEPILEPTICS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 157.17
Logarithm of the Partition Coefficient (xlogp) 0.8
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The drug is rapidly absorbed via the digestive tract []
Half-life
The concentration or amount of drug in body reduced by one-half in 12 - 24 hours [3]
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C7H11NO3
IUPAC Name
5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione
Canonical SMILES
CCC1(C(=O)N(C(=O)O1)C)C
InChI
InChI=1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3
InChIKey
VQASKUSHBVDKGU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
8280
ChEBI ID
CHEMBL7921
CAS Number
115-67-3
UNII
Z615FRW64N
DrugBank ID
DB00617
TTD ID
D09JBP
INTEDE ID
DR1239
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) TT729IR CAC1G_HUMAN Blocker [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [5]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [6]
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Absence epilepsy
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DTT CACNA1G 3.88E-01 -0.06 -0.18
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DTT CACNA1G 9.84E-01 -0.01 -0.03
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 4.20E-02 -1.71E-01 -3.15E-01
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 3.07E-01 -2.23E-02 -1.46E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 8.99E-01 -6.93E-03 -1.36E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 9.21E-01 7.31E-03 6.10E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.66E-01 4.25E-02 1.20E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.75E-01 5.15E-02 3.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Paramethadione (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Levomilnacipran DMV26S8 Moderate Antagonize the effect of Paramethadione when combined with Levomilnacipran. Chronic pain [MG30] [7]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Paramethadione and Olopatadine. Conjunctiva disorder [9A60] [8]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Paramethadione and Ethanol. Cystitis [GC00] [8]
Sertraline DM0FB1J Moderate Antagonize the effect of Paramethadione when combined with Sertraline. Depression [6A70-6A7Z] [7]
Vilazodone DM4LECQ Moderate Antagonize the effect of Paramethadione when combined with Vilazodone. Depression [6A70-6A7Z] [7]
Paroxetine DM5PVQE Moderate Antagonize the effect of Paramethadione when combined with Paroxetine. Depression [6A70-6A7Z] [7]
Vortioxetine DM6F1PU Moderate Antagonize the effect of Paramethadione when combined with Vortioxetine. Depression [6A70-6A7Z] [7]
Milnacipran DMBFE74 Moderate Antagonize the effect of Paramethadione when combined with Milnacipran. Depression [6A70-6A7Z] [7]
Escitalopram DMFK9HG Moderate Antagonize the effect of Paramethadione when combined with Escitalopram. Depression [6A70-6A7Z] [7]
Desvenlafaxine DMHD4PE Moderate Antagonize the effect of Paramethadione when combined with Desvenlafaxine. Depression [6A70-6A7Z] [7]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Paramethadione and Esketamine. Depression [6A70-6A7Z] [9]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Paramethadione when combined with Hydroxychloroquine. Malaria [1F40-1F45] [9]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Paramethadione and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [10]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Paramethadione and Lasmiditan. Migraine [8A80] [11]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Paramethadione and Flibanserin. Mood disorder [6A60-6E23] [12]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Paramethadione and Thalidomide. Multiple myeloma [2A83] [8]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Paramethadione and Ocrelizumab. Multiple sclerosis [8A40] [13]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Paramethadione and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [14]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Paramethadione and Apraclonidine. Optic nerve disorder [9C40] [15]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Paramethadione and Dextropropoxyphene. Pain [MG30-MG3Z] [16]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Paramethadione and Buprenorphine. Pain [MG30-MG3Z] [17]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Paramethadione and Tizanidine. Tonus and reflex abnormality [MB47] [18]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Paramethadione and Ganciclovir. Virus infection [1A24-1D9Z] [9]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Paramethadione and Valganciclovir. Virus infection [1A24-1D9Z] [9]
⏷ Show the Full List of 24 DDI Information of This Drug

References

1 Paramethadione FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7261).
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
5 Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
6 Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther. 2000 Jun;25(3):165-75.
7 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
8 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
9 Cerner Multum, Inc. "Australian Product Information.".
10 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
11 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
12 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
13 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
14 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
15 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
16 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
17 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
18 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.